BeiGene, Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
BGNE Nasdaq 2836 www.beigene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for BeiGene, Ltd.

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets - Dec 10th, 2024 1:30 am
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL - Dec 4th, 2024 11:00 am
BeiGene Gains Overweight Rating from Morgan Stanley with $300 Price Target - Dec 3rd, 2024 9:00 pm
Why Is BeiGene, Ltd. (BGNE) Among the Best High Growth Healthcare Stocks to Invest In Now? - Dec 2nd, 2024 9:08 pm
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 - Dec 2nd, 2024 11:01 am
BeiGene’s PD-1 drug approved in EU for first-line oesophageal cancer treatment - Nov 27th, 2024 5:25 pm
Why Is BeiGene Stock Trading Higher On Wednesday? - Nov 27th, 2024 5:01 pm
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer - Nov 27th, 2024 11:00 am
BeiGene to Present at Upcoming Investor Conferences - Nov 26th, 2024 11:01 am
High Growth Tech Stocks to Watch in November 2024 - Nov 25th, 2024 6:04 pm
Labcorp CFO Glenn Eisenberg Announces Plans to Retire - Nov 19th, 2024 12:00 pm
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA - Nov 19th, 2024 11:00 am
BeiGene, Ltd. (BGNE): Among 12 High Growth Large Cap Stocks to Buy Now - Nov 15th, 2024 5:20 pm
Halozyme bids for Evotec; BeiGene gets a new name - Nov 15th, 2024 10:00 am
BeiGene Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Nov 14th, 2024 11:49 am
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer - Nov 14th, 2024 11:00 am
Decoding BeiGene Ltd (BGNE): A Strategic SWOT Insight - Nov 13th, 2024 5:12 am
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates - Nov 12th, 2024 11:00 am
BeiGene to Present at the Jefferies London Healthcare Conference - Nov 6th, 2024 11:01 am
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 - Nov 5th, 2024 2:05 pm